Potential prognostic determinants for FET::CREB fusion-positive intracranial mesenchymal tumor
Authors:
Open Access
- 30 January 2024
- journal article
- research article
- Published by Springer Nature in Acta Neuropathologica Communications
- Vol. 12 (1) , 1-13
Abstract
Intracranial mesenchymal tumor (IMT), FET::CREB fusion-positive is a provisional tumor type in the 2021 WHO classification of central nervous system tumors with limited information available. Herein, we describe five new IMT cases from four females and one male with three harboring an EWSR1::CREM fusion and two featuring an EWSR1::ATF1 fusion. Uniform manifold approximation and projection of DNA methylation array data placed two cases to the methylation class “IMT, subclass B”, one to “meningioma-benign” and one to “meningioma-intermediate”. A literature review identified 74 cases of IMTs (current five cases included) with a median age of 23 years (range 4–79 years) and a slight female predominance (female/male ratio = 1.55). Among the confirmed fusions, 25 (33.8%) featured an EWSR1::ATF1 fusion, 24 (32.4%) EWSR1::CREB1, 23 (31.1%) EWSR1::CREM, one (1.4%) FUS::CREM, and one (1.4%) EWSR1::CREB3L3. Among 66 patients with follow-up information available (median: 17 months; range: 1–158 months), 26 (39.4%) experienced progression/recurrences (median 10.5 months; range 0–120 months). Ultimately, three patients died of disease, all of whom underwent a subtotal resection for an EWSR1::ATF1 fusion-positive tumor. Outcome analysis revealed subtotal resection as an independent factor associated with a significantly shorter progression free survival (PFS; median: 12 months) compared with gross total resection (median: 60 months; p < 0.001). A younger age (< 14 years) was associated with a shorter PFS (median: 9 months) compared with an older age (median: 49 months; p < 0.05). Infratentorial location was associated with a shorter overall survival compared with supratentorial (p < 0.05). In addition, the EWSR1::ATF1 fusion appeared to be associated with a shorter overall survival compared with the other fusions (p < 0.05). In conclusion, IMT is a locally aggressive tumor with a high recurrence rate. Potential risk factors include subtotal resection, younger age, infratentorial location, and possibly EWSR1::ATF1 fusion. Larger case series are needed to better define prognostic determinants in these tumors.Keywords
This publication has 47 references indexed in Scilit:
- ESWR1-CREM Fusion in an Intracranial Myxoid Angiomatoid Fibrous Histiocytoma-Like Tumor: A Case Report and Literature ReviewJournal of Neuropathology & Experimental Neurology, 2018
- Primary myxoid mesenchymal tumour with intracranial location: report of a case with a EWSR1–ATF1 fusionHistopathology, 2017
- Intracranial myxoid mesenchymal tumors with EWSR1–CREB family gene fusions: myxoid variant of angiomatoid fibrous histiocytoma or novel entity?Brain Pathology, 2017
- EWSR1 Fusions With CREB Family Transcription Factors Define a Novel Myxoid Mesenchymal Tumor With Predilection for Intracranial LocationAmerican Journal of Surgical Pathology, 2017
- Intracranial Angiomatoid Fibrous Histiocytoma: Case Report and Literature ReviewWorld Neurosurgery, 2016
- Primary Intracranial Myoepithelial NeoplasmInternational Journal of Surgical Pathology, 2015
- Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarraysBioinformatics, 2014
- Distant metastases in meningioma: an underestimated problemJournal of Neuro-Oncology, 2013
- Intracranial angiomatoid fibrous histiocytoma presenting as recurrent multifocal intraparenchymal hemorrhageJournal of Neurosurgery, 2010
- Primary Intracerebral Angiomatoid Fibrous HistiocytomaAmerican Journal of Surgical Pathology, 2008